GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

OnCoCross Co 382150.KQ · KRW

N/A · KOSDAQ · 🇰🇷 South Korea

Compare

2,700

-1.64%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About OnCoCross Co

Its shares trade on KOSDAQ under the ticker 382150.KQ. It has been listed since 18 December 2024. In the fiscal year to 31 December 2025, it reported revenue of ₩370.5m and a net loss of ₩8.93bn. At that date it held total assets of ₩28.96bn and shareholders' equity of ₩13.37bn.

OnCoCross Co Ltd is a KR-based company operating in industry. The company is headquartered in Seoul, Seoul. The company went IPO on 2024-12-18. OnCoCross Co Ltd is a Korea-based company primarily engaged in the new drug research and development business. The firm mainly develops artificial intelligence (AI) new drug development platform based on its original technology which analyzing changes in gene expression data (Transcriptome) due to drug administration or disease occurrence and using AI to match the optimal disease and treatment. The firm mainly develops treatments for rare diseases, cancer, dementia and other intractable diseases.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
18 Dec 2024

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • OnCoCross Co Ltd develops AI-driven drug platforms for rare diseases and cancer in Korea.
  • The company focuses on transcriptome analysis using AI for optimal disease treatment matching.
  • Seoul-based headquarters supports access to Korea's biotech innovation ecosystem.

Weaknesses

  • Limited market presence in global pharmaceutical markets outside Korea.
  • Reliance on AI technology for drug development may face technical challenges.
  • Narrow focus on rare diseases could limit broader market opportunities.

Opportunities

  • Growing demand for AI in drug development within the Korean healthcare sector.
  • Expansion into global markets for rare disease treatments beyond Korea.
  • Partnerships with international biotech firms for drug development collaboration.

Threats

  • Intense competition from established pharmaceutical companies in Korea.
  • Regulatory hurdles in drug approval processes for new AI-based treatments.
  • Economic downturns affecting funding for rare disease research initiatives.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.